newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - NATERA INC

  • Explicit Guidance:

    • Revenue Target: Full-year revenue target of $6 billion by 2029 (currently ~$3 billion in 2026).
    • ASP Target: Average Selling Price (ASP) for Signatera targeting $1,450 by 2029 (current ASP ~$1,290).
    • 2026 Revenue: Full-year 2026 revenue guidance reset to north of $3 billion.
  • Business-Segment Outlook:

    • Signatera (Oncology):
      • Market Opportunity: Core business represents a ~$20 billion annual revenue opportunity; currently at ~$1 billion revenue.
      • Volume Growth: Projected to grow 40%+ EBITDA (implied by "growing at 40% plus extra ups") while scaling.
      • New Patient Starts: New patient start volume remains on an upward trajectory; represents 10–15% of total quarterly MRD volumes.
      • ASP Expansion: Potential $200–$300 ASP uplift from securing MolDX coverage across 9 additional tumor types in flight.
      • MolDX Coverage: 9 dossiers currently in flight for new indications; expected FDA/MLDx turnaround time of 9–12 months per submission.
      • Signatera Genome: Full transition anticipated over a 1.5–3 year horizon; clinical trial data for genome backbone with phased structural variants expected to read out in 2027–2028.
      • Clinical Trials: FIND study (early cancer detection, colorectal cancer) data readout scheduled for next year; results expected to double the addressable market.
      • Long-tail Reimbursement: Continued focus on enforcing Medicare Advantage compliance and expanding commercial payer coverage in biomarker states.
    • Early Cancer Detection (ECD):
      • Timeline: Investment of $400–$500 million in R&D prior to commercial launch; launch expected in 3–4 years.
      • Market Size: Addresses 13–14 million potential annual users for colorectal cancer screening alone (once-every-three-years frequency).
      • High-Risk Populations: Potential to expand beyond colorectal cancer to high-risk cohorts, creating a market size comparable to the Signatera core business.
      • Strategic Goal: ECD market expected to "hit its stride" in 2029–2030, effectively doubling the company's total addressable market.
    • Women's Health & Transplant:
      • Outlook: Anticipates modest but continued growth for both women's health (Prospera) and organ health (transplant rejection monitoring) segments.
    • Pharma Services:
      • Growth Driver: Significant acceleration in contracted value and strategic trial partnerships following the positive INVIGOR trial results with Roche.
      • Impact: Enables faster, lower-cost clinical trials for drug approval; potential for massive increase in total contracted value.
  • Market and Competitive Outlook:

    • Competitive Landscape: Recognizes two primary competitors in ECD with strong commercial execution; Natera aims to capture a "fair share" based on comparable performance and commercial track record.
    • Payer Dynamics: Commercial payers demonstrated constructive willingness to cover ECD tests for colorectal cancer, validating the business case.
    • Guideline Adoption: Goal to achieve inclusion in NCCN guidelines for colorectal and breast cancer within the next three years.
    • Differentiation: ECD competitive advantage lies in high patient compliance among the 40 million Americans unable or unwilling to undergo colonoscopies/fecal tests.
  • Macro / Industry Outlook:

    • Payer Environment: Positive outlook on commercial and Medicare Advantage reimbursement trends for molecular diagnostics and ECD.
    • Regulatory Path: Expectation of continued rigorous but predictable MolDX committee reviews (9–12 month cycles).
    • Clinical Utility: High confidence in sustained patient adherence to 5-year surveillance protocols due to demonstrated clinical utility in treatment steering and recurrence monitoring.
  • Strategic Initiatives:

    • CEO Transition: Solomon Moskovich appointed as CEO, succeeding Steve Terra (16-year tenure); "warm handoff" with Steve remaining available as advisor.
    • Technology Obsolescence: Commitment to continuous self-disruption by shifting from exome-based to whole-genome Signatera assays with phased structural variants to enhance sensitivity without increasing false positives.
    • Cost Optimization: Expectation of temporary Cost of Goods Sold (COGS) "bubble costs" associated with genome backbone rollout, expected to normalize within a couple of quarters.
    • Pipeline Expansion: Launching expanded clinical trial protocols to include additional blood samples for parallel Signatera Genome analysis on existing long-dated trials.
  • Risks and Headwinds to Outlook:

    • Execution Risk: Achievement of the $6B target requires "good execution" and "good performance," not just "heroic" assumptions; dependent on hitting volume and ASP marks.
    • Clinical Trial Risk: Success hinges on positive readouts from the FIND study (2027) and other long-dated outcomes trials (2027–2028); failure could impact market validation.
    • Regulatory/Reimbursement Risk: ECD market viability depends on continued constructive payer behavior and eventual FDA clearance based on the FIND study.
    • Competitive Risk: Need to match or exceed competitors' execution in early cancer detection to capture market share.
    • COGS Volatility: Temporary margin compression expected due to higher initial COGS for genome backbone technology.
  • Management Tone on the Future:

    • Confidence Level: Highly confident ("hair on fire with important clinical trials," "nothing that is unrealistic," "eminently achievable").
    • Strategic View: Believes the market opportunity is significantly larger than current penetration ("maybe a billion into it today" of a "$20 billion" opportunity).
    • Leadership Stability: Emphasizes long-tenured management team (co-founders, 11+ year averages) and "friendly transition" to minimize disruption.
    • Growth Narrative: Describes the path to $6B as a "goal" requiring "pen to paper" calculation that proves achievable through core business execution and ASP expansion, rather than an unrealistic "dream."
  • Miscellaneous:

    • Market Scale Math: To reach $6B by 2029, Natera implies scaling Signatera from current levels to millions of tests annually, potentially transforming a $100–$150M R&D investment into a multi-million test revenue generator.
    • Phase Variants: Clarified that phased structural variant technology adds algorithmic capability with minimal additional cost.
Company
NATERA INC
Keywords
NATERA INC